The first batch of EpiVacCorona vaccine passed the control of Roszdravnadzor

RIA Novosti informs about this with reference to the press service of Rospotrebnadzor.

"To date, the first batch of the EpiVacCorona vaccine used in clinical trials has successfully passed the control of Roszdravnadzor," the department said.

Earlier, Russian President Vladimir Putin announced the registration of the second Russian vaccine against coronavirus infection, EpiVacCorona, developed by the Vector Center for Virology and Biotechnology.

Professor of the Department of Virology at the Belozersky Institute of Moscow State University, Alexei Agranovsky, in an interview with URA.RU, assessed the immunity of those vaccinated against COVID-19.